Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -29.51%53.99K | -87.35%27.66K | 18.47%151.4K | 680.60%952.43K | 47.85%529.44K | 160.62%76.59K | 309.07%218.61K | 510.75%127.79K | 115.11%122.01K | 318.53%358.1K |
| Net income from continuing operations | -71.94%64.34K | -157.15%-162.61K | 188.80%129.8K | 256.10%437.08K | -7.41%-122.68K | 3,402.10%229.3K | 1,143.88%284.52K | 131.75%44.94K | 80.65%-280K | 65.83%-114.22K |
| Operating gains losses | --8.11K | ---- | --2.56K | ---- | ---- | ---- | ---- | ---- | 381.40%18.63K | --0 |
| Depreciation and amortization | -66.27%22.45K | 48.41%38.02K | -13.21%100.77K | 257.70%402.57K | 302.55%195.21K | -38.61%66.56K | -72.31%25.62K | 1,319.95%116.11K | 3,249.55%112.55K | -11,064.28%-96.38K |
| Asset impairment expenditure | ---- | ---- | ---- | -88.40%33.65K | ---- | ---- | ---- | ---- | 762.86%290K | ---- |
| Unrealized gains and losses of investment securities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Other non cashItems | -5.19%2.12K | 2,800.84%6.4K | 651.60%1.89K | -8.83%58.85K | 101.13%56.27K | 270.81%2.24K | ---237 | -101.82%-343 | 1,568.11%64.56K | --27.98K |
| Change In working capital | 93.25%-14.96K | 344.31%145.85K | -2.05%-33.59K | 191.59%59.61K | 62.07%406.32K | 3.03%-221.51K | 64.85%-59.7K | -139.45%-32.92K | -115.10%-65.09K | 69.10%250.72K |
| -Change in receivables | 317.00%29.27K | 359.46%43.26K | 169.70%22.91K | 80.02%-35.99K | 2.09%19.07K | 104.91%7.02K | 63.59%-16.67K | -298.68%-32.87K | -1,713.83%-180.17K | 255.08%18.68K |
| -Change in prepaid assets | 98.38%-2.81K | -94.44%1.7K | -102.43%-1.45K | 250.73%97.3K | 301.09%181.09K | -4,174.88%-173.75K | 117.49%30.48K | 722.91%59.48K | -3,190.01%-64.55K | -2,048.38%-90.05K |
| -Change in payables and accrued expense | 13.08%-45.04K | 254.90%124.36K | 7.50%-55.06K | -100.94%-1.7K | -35.06%222.52K | 45.07%-51.82K | 41.85%-80.29K | -199.74%-59.53K | -59.45%179.63K | 12.16%342.64K |
| -Change in other working capital | 222.64%3.62K | -445.95%-23.46K | ---- | ---- | ---- | -162.63%-2.96K | --6.78K | ---- | ---- | ---- |
| Interest paid (cash flow from operating activities) | ---28.07K | --0 | ---47.47K | ---39.34K | ---- | ---- | ---31.59K | --0 | --0 | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -29.51%53.99K | -87.35%27.66K | 18.47%151.4K | 680.60%952.43K | 47.85%529.44K | 160.62%76.59K | 309.07%218.61K | 510.75%127.79K | 115.11%122.01K | 318.53%358.1K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 96.25%-12.02K | 20.50%-71.82K | 20.96%-59.26K | 58.83%-714.26K | 42.36%-228.47K | 15.13%-320.48K | 53.65%-90.33K | 89.99%-74.98K | -24,978.40%-1.73M | -68,718.23%-396.39K |
| Net PPE purchase and sale | 97.02%-9.56K | 29.47%-63.71K | 20.96%-59.26K | 60.20%-714.26K | 42.36%-228.47K | 15.13%-320.48K | 53.65%-90.33K | 90.73%-74.98K | -24,256.19%-1.79M | -38,534.80%-396.39K |
| Net business purchase and sale | ---2.46K | ---8.11K | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Net investment purchase and sale | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | 13,153.33%59.64K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 96.25%-12.02K | 20.50%-71.82K | 20.96%-59.26K | 58.83%-714.26K | 42.36%-228.47K | 15.13%-320.48K | 53.65%-90.33K | 89.99%-74.98K | -24,978.40%-1.73M | -68,718.23%-396.39K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -927.90%-32.02K | -34K | -31.51K | -101.38%-23.14K | -125.68%-20.03K | -100.71%-3.12K | 0 | 0 | 1.68M | 78K |
| Net issuance payments of debt | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | --1.07M | --0 |
| Net common stock issuance | -927.90%-32.02K | ---34K | ---31.51K | ---23.14K | 96.27%-20.03K | -102.40%-3.12K | --0 | --0 | --0 | ---537.4K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --615.4K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -927.90%-32.02K | ---34K | ---31.51K | -101.38%-23.14K | -125.68%-20.03K | -100.71%-3.12K | --0 | --0 | --1.68M | --78K |
| Net cash flow | ||||||||||
| Beginning cash position | 6.41%272.39K | 174.50%350.54K | 287.13%289.92K | 954.18%74.89K | -74.49%8.98K | 158.15%255.98K | 188.89%127.7K | 954.18%74.89K | -99.14%7.1K | -79.49%35.18K |
| Current changes in cash | 104.03%9.95K | -160.92%-78.15K | 14.79%60.63K | 217.22%215.03K | 607.51%280.94K | -286.07%-247.01K | 133.43%128.28K | 42.35%52.81K | 108.32%67.79K | 124.15%39.71K |
| End cash Position | 3,045.40%282.33K | 6.41%272.39K | 174.50%350.54K | 287.13%289.92K | 287.13%289.92K | -74.49%8.98K | 158.15%255.98K | 188.89%127.7K | 954.18%74.89K | 954.18%74.89K |
| Free cash from | 118.21%44.42K | -128.10%-36.05K | 74.46%92.14K | 114.24%238.17K | 885.98%300.97K | 51.61%-243.89K | 142.84%128.28K | 106.29%52.81K | -105.21%-1.67M | 76.78%-38.29K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.